» Articles » PMID: 30704451

Probiotics and Vaginal Microecology: Fact or Fancy?

Overview
Publisher Biomed Central
Date 2019 Feb 2
PMID 30704451
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Probiotics are live microorganisms that, when administered in adequate amounts, should confer a health benefit to the host. Media sources tend to present probiotics as an appealing health promotion method able to prevent or treat a wide variety of clinical conditions. In obstetrics and gynaecology, Lactobacilli species are mainly used to restore the physiologic vaginal microbiota in order to treat bacterial vaginosis and vulvovaginal candidiasis (VVC) and prevent preterm birth.

Discussion: Several RCTs investigated the potential benefits of probiotics in gynaecological and obstetrics conditions. For all potential indications, recent specific meta-analyses have been published. Considering vulvovaginal candidiasis in non-pregnant women, probiotics slightly improved the short-term clinical and mycological cure, and reduced the 1-month relapse. However, no important impact of probiotic use was observed on long-term clinical or mycological cure. Similarly, the addition of probiotics to metronidazole for the treatment of bacterial vaginosis was not shown to provide any additional benefit. In obstetrics, using probiotics during pregnancy neither decreased nor increased the risk of preterm birth before 34 weeks or before 37 weeks. Similarly, no benefits emerged for gestational diabetes, preterm premature rupture of membrane, and small and large for gestational age infants.

Conclusion: Despite increasing marketing of probiotics for the treatment of vulvovaginal candidiasis and prevention of preterm birth robust evidence demonstrating a beneficial effect is scarce. Moreover, there was considerable heterogeneity among the different studies in terms of route of administration, strain/s of probiotic adopted, and length of probiotic use. Before recommending the systematic use of probiotics to treat bacterial vaginosis and VVC and prevent preterm birth, high-quality research is needed. Professional medical associations should issue recommendations defining if, when, and how probiotics should be used for gynaecological disorders.

Citing Articles

Metabarcoding analysis of oral microbiome during pregnancy.

Benslimane F, Mohammed L, Abu-Hijleh H, Suleiman S, Boughattas S, Zakaria Z Front Cell Infect Microbiol. 2025; 14:1477703.

PMID: 39742335 PMC: 11685078. DOI: 10.3389/fcimb.2024.1477703.


Organ-on-a-chip: future of female reproductive pathophysiological models.

Deng Z, Dai F, Wang R, Deng H, Yin T, Cheng Y J Nanobiotechnology. 2024; 22(1):455.

PMID: 39085921 PMC: 11290169. DOI: 10.1186/s12951-024-02651-w.


Phenylacetic acid, an anti-vaginitis metabolite produced by the vaginal symbiotic bacterium Chryseobacterium gleum.

Kwon K, Kim E, Sim K, Lee Y, Kang E, Han K Sci Rep. 2024; 14(1):12226.

PMID: 38806600 PMC: 11133378. DOI: 10.1038/s41598-024-62947-7.


Vulvovaginitis in pregnant women.

Duarte G, Linhares I, Kreitchmann R, Tristao A, Traina E, Canti I Rev Bras Ginecol Obstet. 2024; 46.

PMID: 38765512 PMC: 11075393. DOI: 10.61622/rbgo/2024FPS03.


Effect of Vaginal Microecological Alterations on Female Pelvic Organ Prolapse.

Chen S, Zheng Q, Zhang L, Chen L, Wang J Int Urogynecol J. 2024; 35(4):881-891.

PMID: 38488886 PMC: 11052768. DOI: 10.1007/s00192-024-05759-7.


References
1.
Xie H, Feng D, Wei D, Mei L, Chen H, Wang X . Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017; 11:CD010496. PMC: 6486023. DOI: 10.1002/14651858.CD010496.pub2. View

2.
Olsen P, Williamson M, Traynor V, Georgiou C . The impact of oral probiotics on vaginal Group B Streptococcal colonisation rates in pregnant women: A pilot randomised control study. Women Birth. 2017; 31(1):31-37. DOI: 10.1016/j.wombi.2017.06.012. View

3.
Rutten N, Van der Gugten A, Uiterwaal C, Vlieger A, Rijkers G, van der Ent K . Maternal use of probiotics during pregnancy and effects on their offspring's health in an unselected population. Eur J Pediatr. 2015; 175(2):229-35. PMC: 4724366. DOI: 10.1007/s00431-015-2618-1. View

4.
Daskalakis G, Karambelas A . Vaginal Probiotic Administration in the Management of Preterm Premature Rupture of Membranes. Fetal Diagn Ther. 2016; 42(2):92-98. DOI: 10.1159/000450995. View

5.
Ma L, Su J, Su Y, Sun W, Zeng Z . Probiotics administered intravaginally as a complementary therapy combined with antibiotics for the treatment of bacterial vaginosis: a systematic review protocol. BMJ Open. 2017; 7(10):e019301. PMC: 5706491. DOI: 10.1136/bmjopen-2017-019301. View